This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Perioperative Option Approved in Canada for Patients with Muscle-Invasive Bladder Cancer Unable to Receive Cisplatin-Based Therapy

Newswire.ca - Mon Jun 29, 8:00AM CDT

Health Canada Decision Supported by Evidence from EV-303 Study

KIRKLAND, QC, June 29, 2026 /CNW/ - Pfizer Canada ULC announced today that Health Canada has, under priority review and Project Orbis initiative, approved PADCEV (enfortumab vedotin for injection), in combination with pembrolizumab, as neoadjuvant treatment and then continued after radical cystectomy as adjuvant treatment for adult patients with muscle-invasive bladder cancer (MIBC) who are ineligible for cisplatin-containing chemotherapy. Project Orbis is an initiative of the FDA which provides a framework for coordinating submission and review of oncology products among international health authorities, including Health Canada. This approval is based on data from the EV-303 clinical trial, which evaluated this combination as a treatment option before and after surgery for patients who are ineligible for cisplatin-containing chemotherapy.

Read more at newswire.ca

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).